Delivery Order SPE2DB22D3009-SPE2DB25FBE51
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $63,291.20 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen/mL pharmaceutical supplies. This firm fixed price, competitively awarded delivery order was issued on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 23, 2025, for SKYRIZI 150 mg/ml pen medication. This firm fixed-price contract, valued at $35,400.44, represents a non-competitive set-aside delivery order with an ultimate completion date of July 24, 2025. The award leverages AmerisourceBergen's established position within the federal pharmaceutical supply...
- The Defense Logistics Agency awarded a $89,511.22 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen/mL pharmaceutical products on September 2, 2025, with completion scheduled for September 3, 2025. This firm fixed price contract is non-set-aside and utilizes AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $50,801.12 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of SKYRIZI 150 mg/mL pen/mL, a pharmaceutical product used to treat inflammatory conditions. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by July 24, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of SKYRIZI 150 mg/mL pen medication, valued at $17,239.18. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The delivery is scheduled for completion by August 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of SKYRIZI 150 MG/ML PenML, a pharmaceutical product, with a ceiling value of $26,166.64. This competitively awarded, firm fixed-price delivery order is set to conclude on August 19, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical...
- The Defense Logistics Agency awarded a $17,574.35 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen vials under a firm fixed price contract type. This competitive award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery location is specified as Conshohocken, Pennsylvania, the company's corporate...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $17,097.24 by the Defense Logistics Agency on August 20, 2025, for the supply of SKYRIZI 150 MG/ML per milliliter. This is a firm fixed price contract with no set-aside designation, reflecting a competitively awarded transaction. The contract is scheduled for ultimate completion by August 21, 2025, with performance taking place at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of SKYRIZI 150 mg/ml pens with a ceiling value of $16,459.82. This firm fixed price delivery order, which completes on August 26, 2025, represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,788.01 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen/ml on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBE51Delivery Order
The Defense Logistics Agency awarded a $20,990.24 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of SKYRIZI 150 mg/ml pen/ml, a pharmaceutical product to be delivered to the company's facility in Conshohocken, Pennsylvania. This firm fixed-price delivery order represents a non-competitive set-aside contract and is scheduled for completion by September 5, 2025. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support contract valued through December 2026 that enables the distributor to supply a broad range of medications and medical supplies to military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal vendor for military and veteran healthcare procurement. As a prime contractor under the DLA Troop Support Medical program, the company maintains an extensive portfolio of competitively awarded delivery orders for brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical devices across multiple therapeutic domains. This particular delivery order for SKYRIZI, a specialty pharmaceutical product, reflects the company's ongoing role in supporting the Defense Health Agency and other federal healthcare systems through flexible contract vehicles designed to meet mission-critical medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.0k | 9/4/25 |